Suppression of hypoxia-inducible factor 2α restores p53 activity via Hdm2 and reverses chemoresistance of renal carcinoma cells

Cancer Research

Volumn 69, Issue 23, 2009, Pages 9056-9064

  Roberts, Andrew M ^a   Watson, Ian R ^a,b   Evans, Andrew J ^a,c   Foster, David A ^d   Irwin, Meredith S ^a,b   Ohh, Michael ^a  

^a UNIVERSITY OF TORONTO   (Canada)

^b HOSPITAL FOR SICK CHILDREN   (Canada)

^c PRINCESS MARGARET HOSPITAL   (Canada)

^d CITY UNIVERSITY OF NEW YORK   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

FAS ANTIGEN; HYPOXIA INDUCIBLE FACTOR 2ALPHA; NUTLIN 3; PROTEIN MDM2; PROTEIN P53; SERINE; SHORT HAIRPIN RNA; TUMOR SUPPRESSOR PROTEIN; VON HIPPEL LINDAU PROTEIN;

APOPTOSIS; ARTICLE; CANCER RESISTANCE; CELL DEATH; CELL FRACTIONATION; CLEAR CELL RENAL CELL CARCINOMA; CONTROLLED STUDY; DOWN REGULATION; ENZYME RECONSTITUTION; GENE ACTIVATION; GENE EXPRESSION; GENE MUTATION; GENE REPRESSION; HUMAN; HUMAN CELL; IMMUNOBLOTTING; IMMUNOHISTOCHEMISTRY; IMMUNOPRECIPITATION; KIDNEY CARCINOMA; PRIORITY JOURNAL; PROTEIN DEPLETION; PROTEIN FUNCTION; PROTEIN PROTEIN INTERACTION; TISSUE MICROARRAY;

ANTIBODIES; ANTIGENS, CD95; APOPTOSIS; BASIC HELIX-LOOP-HELIX TRANSCRIPTION FACTORS; CARCINOMA, RENAL CELL; CELL LINE, TUMOR; DOXORUBICIN; DRUG RESISTANCE, NEOPLASM; HUMANS; KIDNEY NEOPLASMS; PHOSPHORYLATION; PROTO-ONCOGENE PROTEINS C-AKT; PROTO-ONCOGENE PROTEINS C-MDM2; TUMOR SUPPRESSOR PROTEIN P53;

EID: 71549151624     PISSN: 00085472     EISSN: 15387445     Source Type: Journal    
DOI: 10.1158/0008-5472.CAN-09-1770     Document Type: Article

References (53)

1. Cohen HT, McGovern FJ. Renal-cell carcinoma. N Engl J Med 2005;353:2477-2490
2. Brugarolas J. Renal-cell carcinoma - molecular pathways and therapies. N Engl J Med 2007;356:185-187 (Pubitemid 46089681)
3. Johnstone RW, Ruefli AA, Lowe SW. Apoptosis: a link between cancer genetics and chemotherapy. Cell 2002;108:153-164
4. Ko LJ, Prives C. p53: puzzle and paradigm. Genes Dev 1996;10:1054-1072
5. Wallace-Brodeur RR, Lowe SW. Clinical implications of p53 mutations. Cell Mol Life Sci 1999;55:64-75.
6. Tomasino RM, Morello V, Tralongo V, et al. p53 expression in human renal cell carcinoma: an immunohistochemical study and a literature outline of the cytogenetic characterization. Pathologica 1994;86:227-233
7. Vasavada SP, Novick AC, Williams BR. P53, bcl-2, and Bax expression in renal cell carcinoma. Urology 1998;51:1057-1061
8. Qi H, Ohh M. The von Hippel-Lindau tumor suppressor protein sensitizes renal cell carcinoma cells to tumor necrosis factor-induced cytotoxicity by suppressing the nuclear factor-κB-dependent antiapoptotic pathway. Cancer Res 2003;63:7076-7080 (Pubitemid 37413442)
9. Yang H, Minamishima YA, Yan Q, et al. pVHL acts as an adaptor to promote the inhibitory phosphorylation of the NF-κB agonist Card9 by CK2. Mol Cell 2007;28:15-27. (Pubitemid 47531976)
10. Gurova KV, Hill JE, Razorenova OV, Chumakov PM, Gudkov AV. p53 pathway in renal cell carcinoma is repressed by a dominant mechanism. Cancer Res 2004;64:1951-1958
11. Warburton HE, Brady M, Vlatkovic N, Linehan WM, Parsons K, Boyd MT. p53 regulation and function in renal cell carcinoma. Cancer Res 2005;65:6498-6503 (Pubitemid 41060681)
12. Haitel A, Wiener HG, Baethge U, Marberger M, Susani M. mdm2 expression as a prognostic indicator in clear cell renal cell carcinoma: comparison with p53 overexpression and clinicopathological parameters. Clin Cancer Res 2000;6:1840-1844 (Pubitemid 30305080)
13. Bond GL, Hu W, Bond EE, et al. A single nucleotide polymorphism in the MDM2 promoter attenuates the p53 tumor suppressor pathway and accelerates tumor formation in humans. Cell 2004;119:591-602. (Pubitemid 39535748)
14. Hirata H, Hinoda Y, Kikuno N, et al. MDM2 SNP309 polymorphism as risk factor for susceptibility and poor prognosis in renal cell carcinoma. Clin Cancer Res 2007;13:4123-4129
15. Kaelin WG, Jr. Molecular basis of the VHL hereditary cancer syndrome. Nat Rev 2002;2:673-682
16. Roberts AM, Ohh M. Beyond the hypoxia-inducible factor-centric tumour suppressor model of von Hippel-Lindau. Curr Opin Oncol 2008;20:83-89 (Pubitemid 350190986)
17. Kondo K, Klco J, Nakamura E, Lechpammer M, Kaelin WG, Jr. Inhibition of HIF is necessary for tumor suppression by the von Hippel-Lindau protein. Cancer Cell 2002;1:237-246
18. Maranchie JK, Vasselli JR, Riss J, Bonifacino JS, Linehan WM, Klausner RD. The contribution of VHL substrate binding and HIF1-α to the phenotype of VHL loss in renal cell carcinoma. Cancer Cell 2002;1:247-255 (Pubitemid 41039149)
19. Brugarolas JB, Vazquez F, Reddy A, Sellers WR, Kaelin WG, Jr. TSC2 regulates VEGF through mTOR-dependent and -independent pathways. Cancer Cell 2003;4:147-158
20. Liu MY, Poellinger L, Walker CL. Up-regulation of hypoxia-inducible factor 2α in renal cell carcinoma associated with loss of Tsc-2 tumor suppressor gene. Cancer Res 2003;63:2675-2680 (Pubitemid 36605212)
21. Gordan JD, Lal P, Dondeti VR, et al. HIF-α effects on c-Myc distinguish two subtypes of sporadic VHL-deficient clear cell renal carcinoma. Cancer Cell 2008;14:435-446
22. Hoffman MA, Ohh M, Yang H, Klco JM, Ivan M, Kaelin WG, Jr. von Hippel-Lindau protein mutants linked to type 2C VHL disease preserve the ability to downregulate HIF. Hum Mol Genet 2001;10:1019-1027 (Pubitemid 32447779)
23. Lonergan KM, Iliopoulos O, Ohh M, et al. Regulation of hypoxia-inducible mRNAs by the von Hippel-Lindau tumor suppressor protein requires binding to complexes containing elongins B/C and Cul2. Mol Cell Biol 1998;18:732-741 (Pubitemid 28063406)
24. Stickle NH, Cheng LS, Watson IR, et al. Expression of p53 in renal carcinoma cells is independent of pVHL. Mutat Res 2005;578:23-32. (Pubitemid 41395308)
25. Maxwell PH, Wiesener MS, Chang GW, et al. The tumour suppressor protein VHL targets hypoxia-inducible factors for oxygen-dependent proteolysis. Nature 1999;399:271-275
26. Kondo K, Kim WY, Lechpammer M, Kaelin WG, Jr. Inhibition of HIF2α is sufficient to suppress pVHL-defective tumor growth. PLoS Biol 2003;1:E83.
27. Ohh M, Yauch RL, Lonergan KM, et al. The von Hippel-Lindau tumor suppressor protein is required for proper assembly of an extracellular fibronectin matrix. Mol Cell 1998;1:959-968 (Pubitemid 128379257)
28. Watson IR, Blanch A, Lin DC, Ohh M, Irwin MS. Mdm2-mediated NEDD8 modification of TAp73 regulates its transactivation function. J Biol Chem 2006;281:34096-34103 (Pubitemid 46036618)
29. Ohh M, Park CW, Ivan M, et al. Ubiquitination of hypoxia-inducible factor requires direct binding to the β-domain of the von Hippel-Lindau protein. Nat Cell Biol 2000;2:423-427 (Pubitemid 30781067)
30. Gervais ML, Henry PC, Saravanan A, et al. Nuclear E-cadherin and VHL immunoreactivity are prognostic indicators of clear-cell renal cell carcinoma. Lab Invest 2007;87:1252-1264 (Pubitemid 350126708)
31. Evans AJ, Russell RC, Roche O, et al. VHL promotes E2 box-dependent E-cadherin transcription by HIF-mediated regulation of SIP1 and snail. Mol Cell Biol 2007;27:157-169 (Pubitemid 46013241)
32. Reed J, Hakam A, Nicosia SV, Coppola D. Significance of Fas receptor protein expression in epithelial ovarian cancer. Hum Pathol 2005;36:971-976 (Pubitemid 41253382)
33. Hyer ML, Sudarshan S, Kim Y, et al. Downregulation of c-FLIP sensitizes DU145 prostate cancer cells to Fas-mediated apoptosis. Cancer Biol Ther 2002;1:401-406
34. Maeda T, Yamada Y, Moriuchi R, et al. Fas gene mutation in the progression of adult Tcell leukemia. J Exp Med 1999;189:1063-1071 (Pubitemid 29169823)
35. Itoh K, Hase H, Kojima H, Saotome K, Nishioka K, Kobata T. Central role of mitochondria and p53 in Fas-mediated apoptosis of rheumatoid synovial fibroblasts. Rheumatology (Oxford) 2004;43:277-285 (Pubitemid 38313174)
36. Li Y, Raffo AJ, Drew L, et al. Fas-mediated apoptosis is dependent on wild-type p53 status in human cancer cells expressing a temperature-sensitive p53 mutant alanine-143. Cancer Res 2003;63:1527-1533 (Pubitemid 36373639)
37. Mayo LD, Donner DB. A phosphatidylinositol 3-kinase/Akt pathway promotes translocation of Mdm2 from the cytoplasm to the nucleus. Proc Natl Acad Sci U S A 2001;98:11598-11603
38. Zhou BP, Liao Y, Xia W, Zou Y, Spohn B, Hung MC. HER-2/neu induces p53 ubiquitination via Akt-mediated MDM2 phosphorylation. Nat Cell Biol 2001;3:973-982 (Pubitemid 34428742)
39. Gunaratnam L, Morley M, Franovic A, et al. Hypoxia inducible factor activates the transforming growth factor-α/epidermal growth factor receptor growth stimulatory pathway in VHL(-/-) renal cell carcinoma cells. J Biol Chem 2003;278:44966-44974 (Pubitemid 37377256)
40. Kaelin WG, Jr. The von Hippel-Lindau tumor suppressor gene and kidney cancer. Clin Cancer Res 2004;10:6290-5S.
41. Alessi DR, Andjelkovic M, Caudwell B, et al. Mechanism of activation of protein kinase B by insulin and IGF-1. EMBO J 1996;15:6541-6551 (Pubitemid 26413787)
42. Manning BD, Cantley LC. AKT/PKB signaling: navigating downstream. Cell 2007;129:1261-1274
43. Ashcroft M, Ludwig RL, Woods DB, et al. Phosphorylation of HDM2 by Akt. Oncogene 2002;21:1955-1962
44. Turner KJ, Moore JW, Jones A, et al. Expression of hypoxia-inducible factors in human renal cancer: relationship to angiogenesis and to the von Hippel-Lindau gene mutation. Cancer Res 2002;62:2957-2961 (Pubitemid 34525785)
45. Salzberg M, Thurlimann B, Bonnefois H, et al. Current concepts of treatment strategies in advanced or recurrent ovarian cancer. Oncology 2005;68:293-298 (Pubitemid 41160956)
46. Singhal SS, Wickramarachchi D, Singhal J, Yadav S, Awasthi YC, Awasthi S. Determinants of differential doxorubicin sensitivity between SCLC and NSCLC. FEBS Lett 2006;580:2258-2264
47. Barbieri E, Mehta P, Chen Z, et al. MDM2 inhibition sensitizes neuroblastoma to chemotherapy-induced apoptotic cell death. Mol Cancer Ther 2006;5:2358-2365 (Pubitemid 44530473)
48. Cao C, Shinohara ET, Subhawong TK, et al. Radio-sensitization of lung cancer by nutlin, an inhibitor of murine double minute 2. Mol Cancer Ther 2006;5:411-417
49. Coll-Mulet L, Iglesias-Serret D, Santidrian AF, et al. MDM2 antagonists activate p53 and synergize with genotoxic drugs in B-cell chronic lymphocytic leukemia cells. Blood 2006;107:4109-4114 (Pubitemid 43726820)
50. Meulmeester E, Maurice MM, Boutell C, et al. Loss of HAUSP-mediated deubiquitination contributes to DNA damage-induced destabilization of Hdmx and Hdm2. Mol Cell 2005;18:565-576 (Pubitemid 40726233)
51. Stommel JM, Wahl GM. Accelerated MDM2 autodegradation induced by DNA-damage kinases is required for p53 activation. EMBO J 2004;23:1547-1556
52. Galban S, Martindale JL, Mazan-Mamczarz K, et al. Influence of the RNA-binding protein HuR in pVHL-regulated p53 expression in renal carcinoma cells. Mol Cell Biol 2003;23:7083-7095 (Pubitemid 37210992)
53. Roe JS, Kim H, Lee SM, Kim ST, Cho EJ, Youn HD. p53 stabilization and transactivation by a von Hippel-Lindau protein. Mol Cell 2006;22:395-405.